Skip to content
10-Q

Quarterly Report

Nuvectis Pharma, Inc. NVCT

0001558370-24-014340

← back to feed
Filed
Nov 5, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 1, 2024 19.32M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $17.17M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $19.13M
Current Liabilities Q3 2024 · Sep 30, 2024 $6.32M
Current Liabilities Q3 2024 · Dec 31, 2023 $6.98M
Total Liabilities Q3 2024 · Sep 30, 2024 $6.32M
Total Liabilities Q3 2024 · Dec 31, 2023 $6.98M
Current Assets Q3 2024 · Sep 30, 2024 $17.31M
Current Assets Q3 2024 · Dec 31, 2023 $19.19M
Total Assets Q3 2024 · Sep 30, 2024 $17.31M
Total Assets Q3 2024 · Dec 31, 2023 $19.19M
Shares Diluted Q3 2024 · Sep 30, 2023 16.1M sh
Shares Diluted Q3 2024 · Sep 30, 2023 15.34M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$12.1M
Stockholders Equity Q3 2024 · Sep 30, 2023 $16.69M
Stockholders Equity Q3 2024 · Jun 30, 2023 $20.33M
Stockholders Equity Q3 2024 · Mar 31, 2023 $12.27M
Stockholders Equity Q3 2024 · Dec 31, 2022 $14.22M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.37
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.02
Eps Basic Q3 2024 · Sep 30, 2023 −$0.37
Eps Basic Q3 2024 · Sep 30, 2023 −$1.02
Sga Expense Q3 2024 · Sep 30, 2023 $1.67M
Sga Expense Q3 2024 · Sep 30, 2023 $4.92M
Rd Expense Q3 2024 · Sep 30, 2023 $4.49M
Rd Expense Q3 2024 · Sep 30, 2023 $11.12M
Net Income Q3 2024 · Sep 30, 2023 −$5.88M
Net Income Q3 2024 · Sep 30, 2023 −$15.64M
Net Income Q3 2024 · Jun 30, 2023 −$5.71M
Net Income Q3 2024 · Mar 31, 2023 −$4.05M
Operating Income Q3 2024 · Sep 30, 2023 −$6.16M
Operating Income Q3 2024 · Sep 30, 2023 −$16.03M